1. Home
  2. SLI vs PRTA Comparison

SLI vs PRTA Comparison

Compare SLI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Lithium Ltd.

SLI

Standard Lithium Ltd.

N/A

Current Price

$2.02

Market Cap

524.3M

Sector

Industrials

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.28

Market Cap

458.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLI
PRTA
Founded
1998
2012
Country
Canada
Ireland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
524.3M
458.4M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
SLI
PRTA
Price
$2.02
$8.28
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$5.25
$19.00
AVG Volume (30 Days)
1.5M
307.4K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
N/A
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$32.04
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$7.73
52 Week High
$6.40
$11.80

Technical Indicators

Market Signals
Indicator
SLI
PRTA
Relative Strength Index (RSI) 33.75 34.27
Support Level $1.91 $8.10
Resistance Level $2.74 $9.36
Average True Range (ATR) 0.14 0.34
MACD -0.05 -0.12
Stochastic Oscillator 5.00 2.22

Price Performance

Historical Comparison
SLI
PRTA

About SLI Standard Lithium Ltd.

Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: